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ABSTRACT 
 
MicroRNAs (miRNAs) contribute to cancer development and drug resistance via cellular biological 
processes, including metabolic pathways. Energy metabolism plays a significant role to maintain tumor 
proliferation in gastrointestinal (GI) cancers. However, the roles of miRNAs and energy metabolism in 
GI cancers are not fully understood. The studies presented in this thesis aim to provide further insights 
into the biological role of miRNAs, energy metabolism, and the interplay between miRNAs and energy 
metabolism in GI cancers, using gastrointestinal stromal tumor (GIST) and colon cancer as the models. 
In Paper I, we explored the downstream target of miR-125a-5p-PTPN18 axis that contributes to 
imatinib resistance in GIST. We found that over-expression of miR-125a-5p and silencing of PTPN18 
increased phosphorylated focal adhesion kinase (pFAK). FAK inhibitor 14, which blocks 
phosphorylation of Y397-FAK, enhances imatinib response in imatinib-resistant GIST cells. 
Furthermore, FAK inhibitor 14 could rescue the imatinib resistance mediated by overexpression of 
miR-125a-5p, suggesting that pFAK is the downstream target of the miR-125a-5p-PTPN18 axis. 
In Paper II, we profiled the bioenergetic phenotype of imatinib-resistant GIST cells. We identified 
two major types of bioenergetics in imatinib-resistant GIST cell lines and clinical samples, i.e. highly 
metabolically active phenotype with higher glycolysis and oxidative phosphorylation (OXPHOS) and 
low OXPHOS types. Metabolic inhibitor assays revealed that imatinib-resistant GIST 882R cells (with 
highly metabolically active phenotype) were more sensitive to glycolysis inhibition than the parental 
GIST 882 cells, while imatinib-resistant GIST T1R cells (with low OXPHOS) were more resistant to 
OXPHOS inhibition than GIST T1. Our study demonstrates metabolic heterogeneity and diverse 
vulnerability of GIST cells to metabolic inhibitors, suggesting the potential of targeting energy 
metabolism for overcoming imatinib resistance in GIST. 
In Paper III, we further explored the relationship between miRNA and imatinib treatment in GIST 
and the effect on OXPHOS. Using microarray and RT-qPCR, we identified miR-483-3p as one of the 
most downregulated miRNAs in imatinib-treated GISTs. Imatinib treatment resulted in 
downregulation of miR-483-3p and upregulation of OXPHOS in imatinib sensitive GIST cells. 
Modulation of miR-483-3p altered protein expression of mitochondrial respiratory Complex II, 
suggesting its involvement in OXPHOS regulation. This study reveals a potential role of miR-483-3p 
in imatinib-induced OXPHOS expression. 
In Paper IV, we investigated the association of metformin treatment, an inhibitor of OXPHOS, with 
patient survival in colorectal cancer. We showed that metformin users were associated with 44% lower 
risk of mortality compared with nonusers. These findings suggest that metformin could be an adjunct 
to standard treatment of colorectal cancer.  
Overall, this thesis work provides new insights into the role of miRNAs and energy metabolism in 
drug response and potential clinical use in GI cancers. 
  
LIST OF SCIENTIFIC PAPERS 
This thesis is based on the following papers, which will be referred to in the text by their Roman 
numerals: 
I. Wen-Kuan Huang, Pinar Akçakaya, Anastasia Gangaev, Linkiat Lee, 
Katarina Zeljic. Praveensingh Hajeri, Erik Berglund, Mehran Ghaderi, Jan 
Åhlén, Robert Bränström, Catharina Larsson and Weng-Onn Lui. miR-125a-
5p regulation increases phosphorylation of FAK that contributes to imatinib 
resistance in gastrointestinal stromal tumors. 
Exp Cell Res 2018 Oct 1;371(1):287-296. 
 
II. Wen-Kuan Huang, Jiwei Gao, Ziqing Chen, Hao Shi, Juan Yuan, Huanhuan 
L. Cui, Chun-Nan Yeh, Robert Bränström, Catharina Larsson, Shuijie Li and 
Weng-Onn Lui. Heterogeneity of metabolic vulnerability in imatinib-resistant 
gastrointestinal stromal tumor. 
Cells 2020 May 26;9(6):1333. 
 
III. Wen-Kuan Huang, Pinar Akçakaya, Katarina Zeljic, Anastasia Gangaev, 
Stefano Caramuta, Robert Bränström, Catharina Larsson and Weng-Onn Lui. 
Imatinib regulates miR-483-3p and oxidative phosphorylation in 
gastrointestinal stromal tumors. 
Manuscript 
 
IV. Wen-Kuan Huang, Shu-Hao Chang, Hung-Chih Hsu, Wen-Chi Chou, Tsai-
Sheng Yang, Jen-Shi Chen, John Wen-Cheng Chang, Yung-Chang Lin, 
Chang-Fu Kuo and Lai-Chu See.  Postdiagnostic metformin use and survival 
of patients with colorectal cancer: A nationwide cohort study. 
Int J Cancer 2020 Oct 1;147(7):1904-1916.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OTHER PUBLICATIONS 
1. Su PJ, Wu MH, Wang HM, Lee CL, Huang WK, Wu CE, Chang HK, 
Chao YK, Tseng CK, Chiu TK, Lin NM, Ye SR, Lee JY, Hsieh CH. 
Circulating Tumour Cells as an Independent Prognostic Factor in 
Patients with Advanced Oesophageal Squamous Cell Carcinoma 
Undergoing Chemoradiotherapy. Sci Rep 2016 Aug 17;6:31423. 
 
2. Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, Wen MS, 
Chen TH, Lin YC, Liaw CC, Hsu CL, Chang JW, Kuo CF, Huang 
WK. Risk of Cardiovascular Ischemic Events After Surgical Castration 
and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate 
Cancer: A Nationwide Cohort Study. J Clin Oncol 2017 Nov 
10;35(32):3697-3705. 
 
3. Kao WH, Kuo CF, Chou IJ, See LC, Huang WK, Chiou MJ, Zhang 
W, Doherty M, Wang CC, Hsu JT, Chen HH, Hong JH. Prostate-
selective α antagonists increase fracture risk in prostate cancer patients 
with and without a history of androgen deprivation therapy: a 
nationwide population-based study. Oncotarget 2018 Jan 2;9(4):5263-
5273. 
 
4. Chou WC, Wu MH, Chang PH, Hsu HC, Chang GJ, Huang WK, Wu 
CE, Hsieh JC. A Prognostic Model Based on Circulating Tumour Cells 
is Useful for Identifying the Poorest Survival Outcome in Patients with 
Metastatic Colorectal Cancer. Int J Biol Sci 2018 Jan 12;14(2):137-146. 
 
5. Huang WK, Juang YY, Chung CC, Chang SH, Chang JW, Lin YC, 
Wang HM, Chang HK, Chen JS, Tsai CS, Yu KH, Kuo CF, See LC. 
Timing and risk of mood disorders requiring psychotropics in long-
term survivors of adult cancers: A nationwide cohort study. J Affect 
Disord 2018 Aug 15;236:80-87. 
 
6. Hou CH, Lee JS, Lin KK, Chang SH, Huang WK, Kuo CF, See LC. 
Endophthalmitis Incidence of Cancer Patients After Cataract Surgery: 
A Nationwide Matched Cohort Study in Taiwan. Am J Ophthalmol 
2019 Mar;199:246-254. 
 
7. Chang PH, Wu MH, Liu SY, Wang HM, Huang WK, Liao CT, Yen 
TC, Ng SH, Chen JS, Lin YC, Lin HC, Hsieh JC. The Prognostic Roles 
of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-
Like Cells, and Programmed Cell Death-1 Expression on Peripheral 
Lymphocytes in Patients with Initially Unresectable, Recurrent or 
Metastatic Head and Neck Cancer: An Exploratory Study of Three 
Biomarkers in One-time Blood Drawing. Cancers (Basel) 2019 Apr 
15;11(4):540. 
 
 
8. Chen DY, Huang WK, Chien-Chia Wu V, Chang WC, Chen JS, 
Chuang CK, Chu PH. Cardiovascular toxicity of immune checkpoint 
inhibitors in cancer patients: A review when cardiology meets immuno-
oncology. J Formos Med Assoc 2019 Aug 20:S0929-6646(19)30408-
5. 
 
9. Lee CH, Hsieh JC, Wu TM, Yeh TS, Wang HM, Lin YC, Chen JS, Lee 
CL, Huang WK, Hung TM, Yen TT, Chan SC, Chou WC, Kuan FC, 
Hu CC, Chang PH. Baseline circulating stem-like cells predict survival 
in patients with metastatic breast Cancer. BMC Cancer 2019 Dec 
2;19(1):1167. 
 
CONTENTS 
1 Introduction ..................................................................................................................... 1 
1.1 Gastrointestinal stromal tumor (GIST) ................................................................. 1 
1.1.1 Clinical and molecular aspects.................................................................. 1 
1.1.2 Imatinib resistance ..................................................................................... 4 
1.1.3 Emerging tyrosine kinase inhibitors (TKIs) ............................................. 6 
1.2 MicroRNA in cancer ............................................................................................. 7 
1.2.1 Biogenesis .................................................................................................. 7 
1.2.2 Aberrant miRNA expression in cancer ..................................................... 8 
1.2.3 Regulation of biological pathways by miRNA ........................................ 9 
1.2.4 Clinical impacts of miRNAs ................................................................... 10 
1.2.5 miRNA in drug resistance ....................................................................... 11 
1.2.6 miRNA in energy metabolism ................................................................ 12 
1.3 Role of miRNAs in GIST .................................................................................... 12 
1.3.1 Aberrant miRNA expression in GIST .................................................... 12 
1.3.2 miRNA involvement in GIST progression ............................................. 13 
1.3.3 Potential role of miRNAs in prognostic prediction and treatment ........ 13 
1.4 Energy metabolism .............................................................................................. 14 
1.4.1 Energy metabolism in cancer .................................................................. 14 
1.4.2 Energy metabolism in GIST ................................................................... 18 
1.4.3 Energy metabolism in colorectal cancer (CRC) ..................................... 18 
2 Aims of the thesis .......................................................................................................... 21 
3 Materials and methods .................................................................................................. 23 
3.1 Cell lines .............................................................................................................. 23 
3.2 Tumor samples .................................................................................................... 23 
3.3 RNA detection and quantification methods ........................................................ 23 
3.3.1 Reverse transcription-quantitative polymerase chain reaction .............. 23 
3.3.2 miRNA microarray .................................................................................. 24 
3.4 Western blot analysis ........................................................................................... 24 
3.5 Transfection ......................................................................................................... 24 
3.5.1 miRNA mimics and inhibitors ................................................................ 24 
3.5.2 Short hairpin RNA .................................................................................. 25 
3.5.3 Small interfering RNA ............................................................................ 25 
3.6 Functional assays ................................................................................................. 25 
3.6.1 Cell viability ............................................................................................ 25 
3.6.2 Cell proliferation ..................................................................................... 25 
3.6.3 Apoptosis ................................................................................................. 26 
3.7 Metabolic assays .................................................................................................. 26 
3.7.1 Mitochondrial bioenergetics ................................................................... 27 
3.7.2 Glycolysis activity ................................................................................... 27 
3.7.3 Mitochondrial mass measurement .......................................................... 27 
3.7.4 Intracellular reactive oxygen species ...................................................... 27 
3.7.5 Glucose uptake ........................................................................................ 28 
3.8 Immunofluorescence ........................................................................................... 28 
3.9 Inhibition of FAK phosphorylation..................................................................... 28 
3.10 Inhibition of glycolysis and oxidative phosphorylation ..................................... 28 
3.11 Statistical analysis ................................................................................................ 29 
4 Results and discussion ................................................................................................... 30 
4.1 miR-125a-5p regulation of FAK phosphorylation in imatinib resistance of 
gastrointestinal stromal tumors (Paper I) ............................................................ 30 
4.1.1 Regulation of FAK phosphorylation by miR-125a-5p and PTPN18 ..... 30 
4.1.2 FAK phosphorylation and imatinib resistance in GIST ......................... 30 
4.1.3 Association of pFAK and FAK levels with clinical outcomes .............. 30 
4.2 Metabolic heterogeneity in imatinib resistant GIST (Paper II) .......................... 31 
4.2.1 Effect of imatinib treatment on OXPHOS and mitochondrial biogenesis31 
4.2.2 Metabolic heterogeneity in GIST cell lines and tumor samples ............ 31 
4.2.3 Inhibition of glycolysis and oxidative phosphorylation on cell viability32 
4.3 Imatinib induced downregulation of miR-483-3p and upregulation of SDH in GIST 
(Paper III) ............................................................................................................. 32 
4.3.1 Deregulation of miRNA induced by imatinib ........................................ 33 
4.3.2 miR-483-3p regulates Complex II expression ........................................ 33 
4.4 Metformin associated with improving survival in CRC (Paper IV) .................. 33 
4.4.1 Characteristics of metformin users versus nonusers .............................. 33 
4.4.2 Metformin use and improving survival in patients with CRC ............... 34 
5 Conclusions ................................................................................................................... 35 
6 Acknowledgements ....................................................................................................... 36 
7 References ..................................................................................................................... 39 
 
  
LIST OF ABBREVIATIONS 
2-DG 
2-NBDG 
 
3-BP 
5-FU 
ABC 
AKT 
ADP 
AMP 
ATP 
AV 
BCL2 
2-deoxy-glucose 
2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2-
deoxyglucose  
3-bromopyruvate 
5-fluorouracil 
ATP-binding cassette 
Protein kinase B 
Adenosine diphosphate 
Adenosine 5´-monophosphate 
Adenosine triphosphate 
Annexin V 
B-cell lymphoma 2 
BRAF v-raf murine sarcoma viral oncogene homolog B1 
CDK 
CI 
COX 
CRC 
Cyclin-dependent kinase 
Confidence interval 
Cytochrome c oxidase complex  
Colorectal cancer 
DOG1 
ECAR 
EMT 
ETV-1 
FAK 
FDG-PET 
FH 
Discovered on GIST-1 
Extracellular acidification rate 
Epithelial-mesenchymal transition 
ETS translocation variant 1 
Focal adhesion kinase 
18F-fluorodeoxyglucose positron emission tomography 
Fumarate hydratase 
GI Gastrointestinal 
GIST 
HIF-1α 
Gastrointestinal stromal tumor 
Hypoxia-inducible factor-1α 
HK Hexokinase  
 IHC Immunohistochemistry 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog 
LDH 
MET 
miRNA 
Lactate dehydrogenase 
Hepatocyte growth factor receptor 
MicroRNA 
mTOR 
NF1 
Mechanistic target of rapamycin kinase 
Neurofibromatosis type 1 
OCR 
ORR 
OXPHOS 
PARP1 
Oxygen consumption rate 
Overall response rate 
Oxidative phosphorylation 
Poly [ADP-ribose] polymerase 1 
PDGFRA 
pFAK 
PGC1α  
 
PI 
PI3K 
Platelet-derived growth factor receptor alpha 
Phosphorylated focal adhesion kinase 
Proxisome proliferator-activated receptor gamma coactivator 
1-alpha 
Propidium iodide 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 
PKCθ 
Pre-miRNA 
Pri-miRNA 
PTPN18 
Protein kinase C theta 
Precursor miRNA 
Primary miRNA 
Tyrosine-protein phosphatase non-receptor type 18 
PTEN 
RISC 
Phosphatase and tensin homolog 
RNA-induced silencing complex  
ROS 
RT-qPCR 
SDH 
shRNA 
siRNA 
TCA  
TGF-β 
Reactive oxygen species 
Reverse transcription-quantitative polymerase chain reaction 
Succinate dehydrogenase 
Short hairpin ribonucleic acid 
Small interfering ribonucleic acid 
Tricarboxylic acid 
Transforming growth factor beta 
 TFAM Transcription factor A, mitochondrial 
TKI Tyrosine kinase inhibitors  
UTR 
ZEB1 
 
Untranslated region 
Zinc finger E-box binding protein 1 
 
 
 
 
 
  
  
 
 
 1 
1 INTRODUCTION 
MicroRNAs (miRNAs) are important regulators in gene expression networks, which can alter 
many biological processes. It is clear that miRNAs play important roles in gastrointestinal (GI) 
cancer development [1]. Energy metabolism has emerged to be potential therapeutic targets in 
cancer. This thesis has focused on miRNAs in regulating imatinib response, energy metabolism, 
and the potential therapeutics of metabolic inhibitor in GI cancers. Here gastrointestinal stromal 
tumor (GIST) was mainly used as the example of GI cancer. 
1.1 GASTROINTESTINAL STROMAL TUMOR (GIST) 
1.1.1 Clinical and molecular aspects 
1.1.1.1 Epidemiology 
GISTs are the commonest mesenchymal tumors of the GI tract. The incidence is rare, 
occurring at a rate of 0.5-2 cases per 100000 people annually [2]. In some regions, such as 
Shanxi - China and Czech republic, its annual incidence has been reported to be as low as 0.4 
and 0.52 cases per 100000 people, respectively [3, 4]. In other parts, such as Korea [5], Taiwan 
[6] and Hong Kong [7], the annual incidence rates are as high as 1.9-2.2 cases per 100000 
people. Registry data from 1992-2000 revealed an annual incidence of 0.68 per 100000 people 
[8]. However, GIST might be significantly under detected due to its asymptomatic nature and 
low malignancy. An autopsy study in elderly subjects reported 2 GISTs per 1000 cases [9], 
indicating that undetected GISTs with low malignant potential may be more common in the 
elderly. Such GISTs may occur more frequently than those of high malignant potential. 
Moreover, GIST incidence may change over time as awareness and diagnosis improve [10]. 
1.1.1.2 Pathology: historical review 
GIST was first described by Mazur and Clark in 1983 as a wide spectrum of 
mesenchymal tumors that are ill defined by immunohistochemistry (IHC) and ultrastructural 
features [11]. Previously, several classifications have been used for GISTs, e.g. malignant 
fibrous histiocytomas, GI autonomic nerve tumors (GANTs), leiomyoblastoma, 
plexosarcomas, GI leiomyoma, sarcomas, or leiomyosarcoma. Given the presence of smooth 
muscle markers and the spindle cell morphology, GISTs were thought to be of smooth muscle 
origin. Later on, through electron microscopy and IHC analyses, they were labeled ‘stromal 
tumors’ given that their features differ from those of classic leiomyosarcoma. A key finding by 
Kindblom et al revealed that GIST cells are closely related to interstitial cells of Cajal based on 
IHC findings [12]. In the same year, Hirota and colleagues identified KIT-activating mutations 
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in most GISTs [13]. KIT (CD117) is a tyrosine kinase proto-oncogene that is highly expressed 
in interstitial cells of Cajal and GISTs. These findings lead to improved diagnosis of GIST and 
revealed the rationale for using tyrosine kinase inhibitors (TKIs) in GIST treatment. 
1.1.1.3 Histopathology and molecular diagnosis  
          The size of GIST can vary from few millimeters to 35 cm and the median is 5-8 cm [9, 
14]. GISTs are often surrounded by a pseudocapsule. At microscopic level, about 70% of GIST 
cells are spindle-shaped. However, about 20% of GISTs are comprised of epithelioid type or a 
mixture of spindle and epithelioid cells. Some GISTs exhibit pleomorphism. Central necrosis 
and cystic degeneration may exist in large GISTs. About 90-95% of GISTs are KIT positive, 
with a membranous, diffuse, mixed or focal staining pattern [15]. PKC-q is abundant and 
constitutively phosphorylated in multiple GISTs. PKC-q staining serves as a diagnostic marker 
of KIT-negative GISTs [16]. DOG1 (discovered on GIST1) has shown remarkably superior 
sensitivity (98%) and specificity for GIST, relative to KIT [17]. Notably, GISTs are generally 
negative for S-100 (95%) and desmin (98%) [18]. Combined IHC analysis of KIT and DOG1, 
or KIT and PKC-q, may be more efficient for GIST diagnosis. 
Activating mutations of the KIT and platelet-derived growth factor receptor alpha 
(PDGFRA) tyrosine kinases are the main factors driving the development of GIST [19]. These 
mutations are found in micro-GIST, suggesting that they are involved in early GIST 
development [20]. 70-75% of GISTs bear a single KIT mutation that affects juxtamembrane 
exon 11 (65%), extracellular domain exon 9 (10-20%), and kinase domains exon 13 (1%) or 
exon 17 (1%) [21]. 5-10% of GISTs have constitutively activating PDGFRA mutations. 80% 
of the PDGFRA-mutated tumors affect exon 18 (D842V mutation), while the others involve 
exon 12 (10-15%) or 14 (1-5%) [22, 23].  
         GISTs lacking KIT or PDGFRA mutations (10-20%) are termed “wild-type”, however, 
they have been shown to bear mutations affecting members of the succinate dehydrogenase 
(SDH) family, and sometimes in neurofibromatosis type 1 (NF1), or BRAF [24]. Thus, GISTs 
can be molecularly grouped into SDH-competent and SDH-deficient classes depending on 
SDH status. SDH-deficient GISTs tend to occur before 30 years of age, and predominantly 
affect females. They also present with multiple gastric lesions, plexiform features, epithelioid 
type, and lymph node metastases [25]. SDH-competent GISTs seldom exhibit the 
aforementioned features.   
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1.1.1.4 GIST-predisposing syndromes 
Although risk factors for sporadic GIST are unknown, Carney’s triad, Carney-Stratakis 
syndrome, and NF1, have been associated with GIST development. NF1 patients have higher 
risk of developing GIST relative to the general population [26]. The GISTs associated with 
NF1 are often multifocal, occur in small intestines, harbor NF1 mutations, and have favorable 
prognosis. The Carney-Stratakis syndrome is rare and linked to germline mutations affecting 
subunits of the SDH complex, including SDHA, SDHB, SDHC, and SDHD [27]. These 
patients present with multifocal gastric GIST and paraganglioma at young age. Carney’s triad 
is a rare non-hereditary syndrome that classically presents with multiple gastric GISTs 
(epithelioid type) in young women, extra-adrenal paraganglioma, and pulmonary chondroma. 
Promoter hypermethylation-mediated SDHC silencing is associated with GIST development 
in Carney’s triad patients [28]. 
1.1.1.5 Clinical presentation  
The median age at GIST diagnosis is 63-69 years and the disease afflicts men and 
women equally [8, 29]. The clinical presentation varies with location, tumor size, and growth 
conditions. GISTs are submucosal tumors, and may appear as ulcers and bleeding by invading 
through the mucosa. These tumors also invade via the serosa, spreading to nearby organs and 
leading to bowel perforation or intra-abdominal rupture. GIST symptoms include hematemesis, 
melena, fainting, and anemia, and may sometimes require emergency surgery. GISTs may also 
be indicated by palpable masses or pain, jaundice, early satiety, dysphagia, abdominal fullness, 
or intestinal obstruction. Although GISTs can affect any part of the GI tract, they most 
commonly affect the stomach (40-60%) and small intestines (30-40%) [8]. GISTs may also 
present as primary tumors in the omentum, mesentery or retroperitoneum [30]. At diagnosis, 
20-25% of patients already have metastatic disease [31]. Metastases mainly affect the liver or 
abdominal cavity. Extra-abdominal metastases are rarely seen.   
1.1.1.6 Prognosis and recurrence risk 
       The malignant potential of GIST varies widely, but even small GISTs (<2 cm diameter) 
may progress rapidly. Tumor size, location, and mitotic index are regarded as prognostic 
indicators [32, 33]. Proliferation index markers, like PCNA and Ki67, are also used to indicate 
prognosis [34]. Tumors arising in the stomach often have favorable outcomes, as opposed to 
those of the small bowel, colon, and rectum. Tumor rupture is positively related to the risk of 
local recurrence. Symptomatic cases may have poorer prognosis than asymptomatic ones [35]. 
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1.1.1.7 Management of localized GIST 
Surgery is the standard treatment for localized GIST and is aimed at en-bloc resection 
and intact capsule preservation to avoid tumor rupture or hemorrhage. A 1-2 cm macroscopic 
margin is considered optimal width for tumor-free margins [36]. However, lymph node 
dissection is not recommended since lymph node metastasis is uncommon in GIST. Surgery-
associated morbidity may be substantial, and up-front surgery may cause extensive organ 
resection. Preoperative imatinib, a KIT and PDGFRA inhibitor, should be considered for tumor 
shrinkage, which may allow organ sparing. Prior to imatinib treatment, a tissue biopsy with 
mutational analysis is recommended. Although optimal duration is undefined, imatinib 
treatment for 6-12 months before surgery often achieves maximal tumor shrinkage. For patients 
at significant risk of recurrence, adjuvant imatinib is suggested for at least 3 years [37]. GISTs 
accompanied with mutations of KIT exon 11 may benefit from adjuvant imatinib, while those 
with PDGFRA D842V mutation or lacking KIT or PDGFRA mutation are unlikely to benefit.  
Patients with KIT exon 9 mutations are often given imatinib at up to 800 mg daily. Follow-up 
imaging at 3- or 4-month intervals is recommended for intermediate or high-risk tumors in the 
first 2 years after surgery since most recurrences occur in this window [37]. For those with low-
risk tumors, a computerized tomography (CT) scan every 6 months for 5 years is advised. 
Surgical resection of primary GIST has been found to yield a 5-year survival rate of 48-70% 
[38, 39]. 
1.1.1.8 Management of advanced GIST 
Approval for the use of imatinib in metastatic GISTs was granted in 2002 based on the 
positive outcomes from the European/Australasian (study 53) and American (study S0033) 
phase III studies [40, 41]. Metastatic or locally advanced GISTs are mainly treated with 
imatinib. For progressing disease treated with imatinib, sunitinib is used as the second-line drug 
[42]. For patients who fail to respond to imatinib and sunitinib, regorafenib is advised as third-
line therapy [43]. Evidence suggests that metastasectomy may improve survival in some 
patients, especially where metastatic lesions cause infection, bleeding, or obstruction. 
1.1.2 Imatinib resistance 
The approval of imatinib led to the development of targeted therapy for targeting the 
impacts of mutations. Cumulative experience using imatinib and clinicopathological analyses 
has contributed to the elucidation of various responses based on the locations of mutations 
(Table 1). For example, the majority of patients with KIT exon 11 mutations benefit from 
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imatinib treatment. However, they generally develop imatinib resistance after about 8-24 
months of disease stabilization or response [44]. 
Table 1: Distribution of KIT and PDGFRA mutations and their associations with imatinib 
response in GIST 
Mutated gene Exon (Percentage) Imatinib response  
KIT  
(70-75%) 
Exon 11 (60-65%) Well responded, while imatinib resistance 
typically occurs after 18 to 24 months of response 
or disease stabilization 
Exon 9 (10-12%) Lower and shorter response compared to exon 11 
Exon 13 (3%) Primary K642E mutation responded well 
Exon 17 (1%) Non-responsive 
PDGFRA 
(5-10%) 
Exon 12 (1%) Responded 
Exon 14 (1%) Responded 
Exon 18, D842V  
(6%) 
Non-responsive 
The most common mechanism of resistance is reactivation of original tyrosine kinases 
via secondary point mutations (or secondary emergence due to selection pressure) (Figure 1). 
46-67% of GIST patients with acquired imatinib resistance bear secondary mutations. Most 
secondary mutations are found in patients with primary KIT exon 11 mutations (73-86%), and 
only 21-33% of patients with KIT exon 9 primary mutations develop secondary mutations [45, 
46]. The commonest secondary KIT mutation in GIST patients with acquired resistance is 
amino acid substitutions clustered on the ATP-binding pocket site (exon 13 or 14) of KIT, such 
as V654A and T670I. Secondary mutations also affect the activation loop (exon 17 or 18), e.g. 
C809G, D816G/H, D820A/E/G/N/V/Y, N822H/K/T/Y, and Y823D, of the same allele as the 
primary mutation [44, 45, 47]. Such mutations occlude the access of imatinib via steric 
hindrance or loss of crucial hydrogen bonds, thus conferring acquired imatinib resistance. KIT 
amplification is also seen in imatinib-resistant patients [48]. These findings show that acquired 
resistance to imatinib involves original tyrosine kinases, but not activation of additional 
signaling pathways, highlighting unique oncogene addiction by these tumors. 
Imatinib resistance may also result from kinase switching, where alternative kinases, 
independent of the original one are activated. In chronic myeloid leukemia, imatinib resistance 
has been shown to rely on upregulation of LYN and HCK. In GIST, activation of focal adhesion 
kinase (FAK) [49], AXL [50], SRC/integrin [51], and hepatocyte growth factor receptor (MET) 
[52] are also thought to mediate acquired imatinib resistance. Additionally, fibroblast growth 
factor receptor 3 (FGFR3) can restore KIT phosphorylation and promote imatinib resistance 
via MAPK signaling activation [53]. Thus, combining imatinib with inhibitors of these kinases 
may enhance anti-tumor effects. 
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Alternatively, some imatinib-resistant tumors can lose KIT expression by loss of 
heterozygosity at the KIT locus, and undergo a phenotypic alteration to an undifferentiated 
phenotype [54]. Additionally, drug influx/efflux mediators also influence imatinib resistance.  
Upregulation of multidrug resistance 1 (MDR1), an ATP-binding cassette (ABC) transporter, 
is known to reduce intracellular levels of chemotherapy agents by extruding them [55].  
Figure 1: Mechanisms involved in acquired imatinib resistance in GIST. Acquired 
secondary KIT mutations that hinder imatinib binding are the commonest resistance 
mechanism. Other mechanisms include kinase switching from KIT to other receptor tyrosine 
kinases, and phenotypic alterations in which tumor cells lose KIT expression and undergo 
phenotypic changes to dedifferentiated phenotype (Courtesy of Pinar Akcakaya). 
 
1.1.3 Emerging tyrosine kinase inhibitors (TKIs) 
The limited efficacy seen with 2nd and 3rd line TKIs indicates that there is an urgent need 
to overcome TKIs resistance in GIST. To this end, the targeted drugs, avapritinib (BLU-285) 
and ripretinib (DCC-2618) are in international phase III studies. Ripretinib is a type II kinase 
inhibitor with a “switch-control” function that forces the activation loop into an inactive 
conformation by restoring juxtamembrane domain inhibitory switch [56]. Recently preliminary 
findings of the phase III study (Invictus) was released, which revealed a median progression-
free survival of 6.3 vs 1 month for ripretinib vs. placebo in heavily-treated patients (>3 lines of 
treatment) [57]. However, the overall survival benefits have not been released. Notably, the 
objective response rate of ripretinib was 9.4%, which is similar to sunitinib or regorafenib. A 
summary of recent advances in targeted therapies for GIST treatment is shown in Table 2. 
 
Table 2: Selected targeted drugs overcoming imatinib resistance or immunotherapy in GIST  
Drug 
(Manufacturer) Mechanism 
Study 
phase Anti-tumor efficacy 
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Avapritinib 
(Blueprint) 
A selective inhibitor of 
KIT and PDGFRA 
activation loop mutants, 
including KIT exon 17 
and PDGFRA exon 18 
D842V 
I 
In the updated data of phase I 
NAVIGATOR trial (n=237), the 
overall response rate (ORR) for patients 
with more than 4 lines treatment failure 
(n=111) was 22%. 52 patients (47%) 
had stable disease with the median 
duration of response (mDOR) of 10.2 
months. Most adverse events (AE) were 
grade 1-2. Of them, memory 
impairment (29%) is the most common 
cognitive AE. The unprecedented 
activity in ORR and mDOR suggests 
avapritinib having a potential to change 
the treatment paradigm. However, 
recently T670I gatekeeper mutation 
was evidenced to confer avapritinib 
resistance [58].   
Ripretinib 
(Deciphera) 
An inhibitor of full 
spectrum of mutant KIT 
and PDGFRA kinases 
with “switch-control” 
ability  
III 
In the phase III INVICTUS trial, 
ripretinib (DCC-2618) demonstrated a 
dramatic improvement in progression-
free survival (PFS) compared with 
placebo (6.3 months vs. 1 month) [57].  
Cabozantinib 
(Exelixis) 
A TKI targeting KIT/ 
MET/AXL/VEGFR II 
30 of the 50 patients (60%) had 
progression-free disease at week 12. 7 
patients (14%) achieved a partial 
response and 33 (66%) had stable 
disease [59].   
Although sunitinib and sorafenib are known to be active against GIST after imatinib 
failure, their clinical efficacy is limited by lower tumor response rate and shorter progression-
free survival relative to imatinib, indicating that KIT-mediated resistance remains a major 
hurdle to effective anti-tumor therapy. Emerging anti-KIT agents, such as ripretinib or 
avapritinib, may improve GIST prognosis after imatinib failure. However, regorafenib, a potent 
inhibitor of exon 17/18 mutations, has not exhibited satisfactory results in clinical trials. Thus, 
the signaling pathways with potential alternative therapeutic targets to overcome drug 
resistance remain elusive. 
1.2 MICRORNA IN CANCER 
1.2.1 Biogenesis 
miRNAs are a class of multifunctional short non-coding RNAs that modulate the 
stability and/or translation of target mRNAs. Through sequence-specific interaction with the 
3’-untranslated region (UTR) of target mRNA, miRNAs suppress gene expression by 
triggering transcript degradation or inhibition of protein translation. More than 2600 mature 
miRNAs have been identified in various human tissues and cells based on miRBase release 
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22.1 (October 2018) [60]. miRNA biogenesis begins with RNA polymerase II mediated 
synthesis of primary miRNAs (pri-miRNAs), which are about 1 kb long. Pri-miRNAs are then 
processed in the nucleus by a microprocessor complex comprised of Drosha and DiGeorge 
syndrome critical region 8 (DGCR8) into precursor miRNAs (pre-miRNAs) (50-110 bp long) 
with stem-loop-stem structures. The pre-miRNA is then transported from the nucleus into the 
cytoplasm by exportin-5, a pre-miRNA-specific export carrier on the nuclear membrane. The 
terminal loop of pre-miRNAs is removed by RNase III Dicer and TAR RNA binding protein 
2 (TARBP2) complex, generating double-stranded miRNAs that are about 18-26 bp long. The 
mature miRNA is incorporated into RNA-induced silencing complex (RISC), a 
ribonucleoprotein complex. The miR-RISC complex enables base-pairing interaction between 
a miRNA and its target RNA’s binding site, mediated by Argonaute (AGO) and various 
cofactors. This interaction may cause translational repression or mRNA degradation via 
endonucleolytic cleavage or deadenylation of target mRNA. The precise mechanism may 
depend on the base-pairing complementarity between the miRNA and target mRNA [61].  
1.2.2 Aberrant miRNA expression in cancer 
miRNAs were first implicated in cancer when Calin et al. found that miR-15 and miR-
16 hosted in chromosome 13q14, are downregulated in about 68% of patients with chronic 
lymphocytic leukemia [62]. Subsequent studies revealed that miRNA expression signatures 
can accurately classify cancer types [63], including hepatocellular carcinoma [64],  colon 
cancer [65], and bladder cancer [66]. These studies offered a rationale for miRNA as diagnostic 
tools. 
MiRNA dysregulation may occur via chromosomal abnormalities, transcriptional 
changes, epigenetic modifications, and defects in the miRNA synthesis machinery. 
Amplification or deletion of genomic regions containing miRNA genes may contribute to 
abnormal miRNA expressions. For example, miR-143 and miR-145 in the 5q33 region are often 
deleted in lung cancer, causing their downregulation [67]. In contrast, the 13q31 region 
harboring the mir-17~92 cluster gene is often overexpressed in lung cancers [68]. MiRNA 
transcription may be controlled by various transcription factors. The oncogenic mir-17~92 
cluster is activated by c-Myc or E2F [69, 70]. Wang et al. found a double-negative feedback 
loop between c-Myc and miR-122, a tumor suppressor in hepatocellular carcinoma [71]. p53 
induces miR-34a expression via direct binding to its promoter region, promoting cell apoptosis 
[72]. miRNAs are susceptible to epigenetic modulation, including global hypomethylation, 
CpG island hypermethylation, histone modifications, and nucleosomal remodeling. The 
aberrant fusion protein AML1/ETO, most commonly found in acute myeloid leukemia, directly 
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suppresses miR-223 expression via CpG island hypermethylation [73]. MiR-127, which targets 
the BCL6 proto-oncogene, is embedded in a CpG island and is subjected to epigenetic silencing 
in cancer [74]. In addition, mutation or deregulation of miRNA processing factors can also alter 
miRNA expression. For example, DGCR8 and Drosha mutations alter the expression of let-7a 
and miR-200 family members in Wilm’s tumors [75]. 
1.2.3 Regulation of biological pathways by miRNA  
The role of miRNAs in tumorigenesis has been extensively studied. Aberrant cell cycle 
activation in cancer is attributed to cyclins, cyclin-dependent kinases (CDKs) and their 
inhibitors, which are widely modulated by miRNAs. MiR-15a and miR-16-1 cause cell cycle 
arrest at G1 by targeting cyclin D, cyclin E, and CDK6 [76, 77]. In breast cancer, cyclin D1, 
which is regulated by miR-17/20, controls cell cycle progression [78]. In gastric cancer, miR-
221/222 directly suppresses the CDK inhibitors p27KIP1 and p57KIP2, thereby facilitating G1/S 
phase transition [79]. Modulation of p27 KIP1 by miR-221/222 has also been found in 
glioblastoma [80],  prostate cancer [81], and thyroid cancer [82], implicating miR-221/222 
mediated regulation of p27KIP1 as a common oncogenic pathway in several cancer types. Multiple 
miRNAs influence resistance to cell death. Downregulation of miR-15a and miR-16-1 
promotes cancer cell proliferation by elevating levels of B-cell lymphoma 2 (BCL2), an anti-
apoptotic factor [83, 84]. Multiple p53-regulated miRNAs have been implicated in a feedback 
loop with p53. MiR-192, miR-194 and miR-215, which are activated by p53, directly suppress 
Mdm2 expression that prevents p53 degradation in multiple myeloma [85].  In hypoxic 
conditions, the miR-17~92 cluster is downregulated by p53, leading to apoptosis [86]. Thus, 
p53 and associated miRNAs form a network that mediates resistance to cell death.  
MiRNAs may also regulate epithelial-mesenchymal transition (EMT) by targeting 
transforming growth factor beta (TGF-β) or other EMT-associated pathways. TGF-β/SMAD4 
signaling activates miR-155, which targets RhoA GTPase, an important modulator of cell 
migration and invasion [87]. The transcription factors ZEB1/2 are well known EMT regulators, 
and together with the miR-200 family, form a double-negative feedback loop to regulate cancer 
cell invasion [88]. Several miRNAs, including miR-203, miR-9, and miR-212 influence cancer 
metastases by modulating key transcription factors, including SNAI2, c-Myc, and MnSOD 
[89-91]. MiRNAs promote angiogenesis, particularly in hypoxic conditions. miR-210 is the 
most consistently induced miRNA under hypoxia. miR-210 facilitates angiogenesis by 
targeting the receptor tyrosine kinase ligand ephrin-A3, which is an antiangiogenic factor, 
thereby enhancing VEGF receptor-2 expression [92, 93]. Thus, miRNAs may exhibit tumor 
suppressive or oncogenic function by modulating various pathways. 
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1.2.4 Clinical impacts of miRNAs 
1.2.4.1 Diagnosis 
The miRNA expression levels may identify tumor origins, suggesting the presence of 
cancer tissue-specific miRNA expression profiles [94]. Multiple studies have suggested 
miRNAs as diagnostic biomarkers for specific cancers. For example, miR-192, miR-215 and 
miR-148a are tumor suppressors in colorectal cancer (CRC), and their downregulation is used 
as diagnostic biomarkers [95]. Various circulating miRNAs, including miR-215, miR-299-5p 
and miR-411 are breast cancer biomarkers [96]. miR-21, miR-126, miR-486-5p, and miR-210 
have exhibited remarkable diagnostic efficiency in non-small cell lung cancer [97]. miR-205 
and miR-21 overexpression in pancreatic ductal adenocarcinoma precedes pancreatic ducts 
phenotypic changes, suggesting their potential value in early detection [98]. Furthermore, 
miRNA profiles can identify cancer subtypes, including basal and luminal breast cancers [99]. 
However, the clinical use of miRNAs as diagnostic biomarkers still requires comprehensive 
validation in a large cohort. 
1.2.4.2 Prognosis 
Multiple studies have highlighted miRNAs as cancer prognostic biomarkers. Calin et 
al. identified a specific miRNA signature associated with progression and prognosis of chronic 
lymphocytic leukemia [100]. miR-155 overexpression and let-7a downregulation are 
associated with poor prognosis in lung cancer [101]. miR-210 upregulation has been linked to 
poor clinical outcomes in triple negative breast cancer [102, 103]. However, the use of miRNAs 
as prognostic markers in clinical practice is constrained by poor understanding of whether they 
are reproducible and disease specific. Further prospective studies are warranted to validate their 
prognostic power. 
1.2.4.3 Potential therapeutic application in pre-clinical models 
MiRNA-based therapies include miRNA mimics and inhibitors (anti-miRs). MiRNA 
mimics are small chemically modified RNA molecules matching the corresponding 
endogenous mature miRNA. These agents are designed to functionally replace lost miRNA 
expression. In contrast, anti-miRs are single-stranded antisense oligonucleotides with chemical 
modifications that block miRNA function. Kasinski et al. showed that nanodelivery of miR-34 
and let-7 suppressed tumor growth in a murine model of non-small cell lung cancer by 
suppressing expression of the tumor promoters Lin28b, c-Met and Myc [104]. Two 
independent studies found that miR-520e and miR-375 suppress liver cancer cell growth in 
xenograft models [105, 106]. Inhibition of oncogenic miR-21 expression combined with 
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gemcitabine promotes apoptosis in a mouse model of pancreatic ductal adenocarcinoma [107]. 
Although their therapeutic use is attractive, few miRNA mimics or inhibitors have entered 
clinical development. Their clinical use is constrained by lack of effective, and safe delivery 
systems [108]. 
1.2.5 miRNA in drug resistance 
miRNA may play different roles in regulating drug resistance in different cellular 
contexts. For example, let-7b enhances tamoxifen sensitivity by targeting estrogen receptor 
alpha signaling in breast cancer [109]. In contrast, in ovarian cancer, let-7b reduces taxane 
sensitivity via downregulating insulin like growth factor 2 mRNA binding protein 1 (IMP-1), 
which is an RNA binding protein stabilizing a number of target genes [110]. MiRNAs can 
regulate drug resistance through different biological processes such as drug metabolism. For 
example, downregulation of CYP3A4 by miR-27b was found to cause cyclophosphamide 
resistance in pancreatic cancer cells [111]. MiRNAs can regulate drug transporters to affect 
chemotherapy sensitivity. miR-298, miR-145 and miR-451 regulate doxorubicin sensitivity by 
targeting the P-glycoprotein drug transporter in breast cancers [112]. Furthermore, miRNAs 
can also target DNA repair genes to alter the chemotherapy response. For example, MutS 
Homolog 2 (MSH2) and MSH6 were downregulated by miR-21 to confer 5-fluorouracil 
resistance [113]. MiRNAs can enhance drug resistance by regulating key genes involved in cell 
proliferation and apoptosis-related signaling pathways. For example, PTEN/AKT pathway is a 
target of miR-21 or miR-214 to induce chemotherapy resistance in cholangiocarcinoma or 
ovarian cancer, respectively [114, 115]. Additionally, miRNAs can regulate key genes 
associated with apoptosis. Bcl-2 is an anti-apoptotic protein in the Bcl-2 gene family. Inhibition 
of miR-15a/16 upregulates BCL-2 expression and promotes tamoxifen resistance in breast 
tumor cells [116]. Of note, miRNAs play roles in targeted drug resistance by modulating genes 
associated with EMT. MiR-200c regulates trastuzumab by targeting Zinc finger protein 217 
(ZNF217) and Zinc finger E-box binding protein 1 (ZEB1) in breast cancer [117]. TGFβ-miR-
200-mitogen-inducible gene 6 (MIG6) signaling was found to orchestrate the EMT-associated 
kinase switch that induces resistance to gefitinib [118]. Since miRNAs can effectively regulate 
chemotherapy response in tumor cells, the use of chemotherapy in combination with 
modulation of miRNA is an optimal strategy to achieve a better response. Wu et al. found that 
miR-27b could enhance the anticancer effect by activating p53 and inhibiting CYP1B1, 
demonstrating that the synergistic effect in combination of miRNA in cancer treatment [119]. 
Furthermore, several studies showed that co-encapsulation of miRNAs with small molecule 
drugs in a nanocarrier, such as miR-205 and gemcitabine for pancreatic cancer treatment [120]. 
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Further investigations are warranted to evaluate the combinatorial effect of miRNA 
therapeutics and anti-cancer treatment for overcoming drug resistance. 
1.2.6 miRNA in energy metabolism 
 
 Bioenergetic reprogramming is an emerging hallmark of cancer cells [121]. Several 
studies found that miRNAs play crucial roles in modulating energy metabolism in cancer cells. 
For example, miR-155 has been reported to enhance glycolysis through activation of 
hexokinase 2 (HK2), an enzyme for the irreversible first step of glycolysis [122]. Tricarboxylic 
acid (TCA) cycle can also be regulated by miR-155. Silencing of miR-155 leads to reduced 
expression of two thiamine transporters, SLC19A2 and SLC25A19, with a concordant 
reduction in thiamine [123]. MiR-378-3p can suppress TCA cycle by direct targeting of 
ERRγ and GA-binding protein alpha chain (GABPA) [124]. cMyc suppresses miR-23a/b and 
thereby leads to upregulation of mitochondrial glutaminase, enhancing glutaminolysis, which 
is also a common metabolic reprograming seen in cancer cells [125]. Upregulation of 
hypoxia-inducible factor-1α (HIF-1α) under hypoxia suppresses the expression of miR-199a-
5p, which can directly target the 3’-UTR of HK2 [126]. Thus, miR-199a-5p/HK2 
reprogramming enhances glycolysis in liver cancer cells, promoting cell proliferation and 
tumorigenesis. HK2 can also be targeted by miR-143 in head and neck squamous cell 
carcinoma, breast cancer, and colon cancer [122, 127, 128]. On the other hand, miRNAs can 
regulate transcripts of TCA cycle or electronic transport chain in cancer cells. For instance, 
miR-183 downregulates isocitrate dehydrogenase 2 (IDH2) that leads to induction of HIF-1α 
in glioma cells [129]. SDH targeted by miR-210 is able to activate HIF-1 and the consequences 
on cell metabolism and survival [130]. The nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) 
signaling pathway suppresses the expression of miR-181c, which can directly downregulate 
cytochrome c oxidase complex 1 (COX1) [131]. COX4 is found to be the direct target of miR-
338 [132]. Altogether, these findings showed that miRNAs can alter energy metabolism 
processes by regulating metabolism-associated genes. 
 
1.3 ROLE OF MIRNAS IN GIST 
1.3.1 Aberrant miRNA expression in GIST 
          miRNA profiling of GIST was first reported in 2008, which was found distinct from 
other sarcoma types [133]. Notably, expression of mir-221~222 and mir-17~92 clusters was 
found to be downregulated relative to other sarcomas. KIT and ETS translocation variant 1 
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(ETV-1), the key oncogenes in GIST, are direct targets of the mir-221~222 and mir-17~92 
clusters, respectively [134], suggesting that these miRNAs may influence tumorigenesis. 
Moreover, miRNA profiles can distinguish between KIT-mutated vs PDGFRA-mutated [135], 
high-risk vs low-risk [136, 137], imatinib-sensitive vs resistant [138], and metastatic vs. non-
metastatic GISTs [138].  
1.3.2 miRNA involvement in GIST progression 
Multiple dysregulated miRNAs are associated with apoptosis and cell proliferation in 
GIST. MiR-222/221 induces apoptosis via KIT/AKT signaling [139, 140]. Loss of 14q is 
common in GIST. MiR-494, a miRNA located in this region, functionally suppresses GIST 
growth by targeting KIT and survivin [141, 142]. Downregulation of miR-133b and 
overexpression of fascin-1 may contribute to GIST aggressiveness [137]. MiR-17/20a directly 
suppresses ETV-1, inducing apoptosis [134]. Some miRNAs have been reported to regulate 
imatinib response. MiR-518a-5p downregulation enhances Phosphatidylinositol-4-phosphate 
3-kinase C2 domain-containing beta polypeptide (PIK3C2A) expression, leading to imatinib 
resistance [143]. PTPN18 suppression via miR-125a upregulation causes imatinib resistance 
[138]. Thus, in GIST, miRNA dyregulation mediates invasion, proliferation, apoptosis or 
imatinib resistance via key molecular pathways. 
1.3.3 Potential role of miRNAs in prognostic prediction and treatment 
Upregulation of miR-196a is associated with high-risk grade, metastasis and poor 
prognosis [144], while downregulation of miR-186 associates with metastatic recurrence and 
poor survival in GIST [145]. High miR-1915 levels associate with improved survival in GIST 
patients [138]. These reports indicate a potential role for miRNAs as prognostic markers. 
However, further studies to validate these miRNAs in combination with known prognostic 
factors, including tumor location, size, and mitotic index, are necessary. Application of 
miRNAs in GIST treatment, especially in rescuing imatinib resistance, is a major clinical 
challenge. However, in pre-clinical studies, miR-218 loaded nanoparticles have been 
demonstrated to suppress GIST growth, and overexpression of miR-218 enhances imatinib 
response in GIST cells [146]. Chemically modified miR-221/222, with altered nucleotides in 
the seed region, are effective suppressors of KIT expression, and may therefore help to 
overcome imatinib resistance [134]. To date, miRNAs have not entered clinical trials for GIST 
treatment and their clinical value remains to be determined. 
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1.4 ENERGY METABOLISM 
1.4.1 Energy metabolism in cancer 
All cells need catabolites to maintain energy metabolism for cell growth and division. 
It has long been recognized that tumor cells require higher demand of energy metabolism. 
The central axis of energy metabolism consists of glycolysis and TCA cycle coupling with 
OXPHOS. Glucose can be catabolized through glycolysis with generation of lactate and 2 
moles of adenosine triphosphate (ATP) per mole of glucose. Further metabolism of pyruvate 
from glycolysis in the mitochondria can generate 36 moles of ATP per mole of glucose via 
the TCA-OXPHOS cycle, which is 18 times more than the amount from glycolysis [147]. 
Although cells use both pathways, one pathway frequently dominates to maintain 
bioenergetic requirement.  
Approximately one century ago, Warburg discovered a bioenergetic difference 
between cancer and normal cells, in which cancer cells tend to utilize glycolysis and produce 
lactate, while normal cells use TCA-OXPHOS cycle to generate ATP and release CO2 (Figure 
2) [148]. Several hypotheses explain why the “Warburg effect” preferentially happens in 
tumor cells. First, OXPHOS is not effective for cell proliferation especially when the 
resources are scarce in the microenvironment. Second, the glycolytic switch in tumor cells 
not only produces effective ATP supply but also provides glycolytic intermediates to 
supplement biosynthetic pathways, which are responsible for synthesis of the 
biomacromolecules such as nucleotides and amino acids required for proliferating tumor 
cells. Excess lactate, typically a metabolic waste product derived from glycolysis, is utilized 
for ATP production and biomacromolecules synthesis [149]. Stromal cells and neighboring 
tumor cells can utilize lactate derived from glycolysis-dominant tumor cells to produce 
pyruvate, which in turn can refuel tumor cells. Anaerobic tumor cells, aerobic 
nontransformed stromal cells and neighboring tumor cells thereby form the cancer symbiosis 
relationship (Figure 3) [150]. Furthermore, glutamine is also utilized for synthesizing 
macromolecules, such as production of nonessential amino acids, lipids, and nucleotides, in 
tumor cells. 
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Figure 2. Energy metabolisms from classical Warburg effect. Cancer cells utilize glycolysis, while 
normal cells use the TCA cycle for ATP production.  
 
 
Figure 3. Cancer cell symbiosis model. The lactate can be utilized by neighboring tumor cells or 
stromal cells for energy refuel or macromolecules biosynthesis.   
 
 The Warburg metabolism forms the basis of 18F-fluorodeoxyglucose positron emission 
tomography (FDG-PET) imaging. At the first step of glycolytic process, glucose is converted 
to glucose-6-phosphate (G-6-P) by HK enzymes.  There are four HK isoenzymes in 
mammalian cells. Among them, HK2 is predominantly expressed in tumor cells. 2-18F-fluoro-
2-deoxy-D-glucose (FDG) can be phosphorylated by mitochondrial bound HK2 to FDG-6-
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phosphate, which is unable to be metabolized further and thereby accumulate in the tumor 
cells with higher level than that in normal cells.  
Otto Warburg’s hypothesis led to the widely held misconception that cancer cells rely 
on glycolysis as their major source of ATP [151]. Although Warburg initially claimed that 
the effect of glycolysis taken by tumor cells even in the presence of ambient oxygen is due 
to impaired mitochondria, subsequent studies found that the mitochondrial function in tumor 
cells is intact [147]. To date we know that it is not impaired mitochondria but several gene 
mutations involving in energy metabolism contribute the shift from OXPHOS to glycolysis 
[152]. For example, several oncogenes, such as HIF-1α, MYC, phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K), AKT and mechanistic target of rapamycin kinase (mTOR), 
can upregulate transcription of genes encoding glycolysis-associated proteins. Wild type 
TP53, a master tumor suppressor gene, suppresses glycolysis, while mutant p53 is known to 
increase glycolysis in tumor cells. Furthermore, reducing ATP production by inhibition of 
pyruvate kinase fails to restrain tumorigenesis, suggesting that using glycolysis to supply 
ATP is not the major function to support tumor growth [153]. Several studies have revealed 
that majority of tumor cells also have the capacity to produce ATP through OXPHOS [154]. 
Moreover, tumorigenesis and tumor cell proliferation have been shown to rely on 
mitochondrial metabolism [155]. Mutations in enzymes involved in TCA cycle, such as SDH 
and fumarate hydratase (FH), might be exceptions. However, cancer cells with mutations in 
FH or SDH still metabolically rewire to mitochondrial metabolism to provide TCA cycle 
intermediates for further macromolecules biosynthesis [149, 156, 157].   
In addition to pyruvate derived from glycolysis, fatty acids and amino acids can supply 
substrates to the TCA cycle to maintain oxidative ATP production in cancer cells. Fatty acids 
are catalyzed to acetyl-CoA through β-oxidation in the mitochondria and generate the 
reducing NADH and FADH2 co-factors, which transfer electrons to oxygen for 
mitochondrial ATP production. The amino acid glutamine metabolism can generate α-
ketoglutarate to supplement the TCA cycle through glutaminolysis [158]. Furthermore, 
elevation of circulating branched chain amino acids isoleucine, valine, and leucine can be 
catabolised to acetyl-CoA and other TCA cycle intermediates [159]. The metabolic flexibility 
allowing multiple inputs into the TCA cycle that provides fuels to cancer cells, which allow 
them to respond to changing microenvironment such as hypoxia or nutrition depletion.   
        Tumor cells bioenergetically adapt to stress microenvironment by sensing the ATP/ 
adenosine diphosphate (ADP) ratio. In nutrition-deficient environment, tumor cells decrease 
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the demand of ATP to increase the available ATP, thereby sustaining the ATP/ADP ratio. If 
diminishing ATP demand is not able to maintain the ATP/ADP ratio, the rise in ADP 
activates adenylate kinase, which converts two ADP molecules into 1 molecule adenosine 
5´-monophosphate (AMP) and 1 molecule ATP [160]. The rise in AMP during nutrient 
deprivation triggers the activation of AMP kinase (AMPK), facilitating catabolic pathways 
like fatty acid oxidation, glycolysis and pentose phosphate pathway (PPP), to stimulate ATP 
production. For example, hypoxic or Ras-driven cancer cells consume lipids to support ATP 
production under starvation condition [161]. Therefore cancer cells maintain their ATP/ADP 
ratio to sustain nutrient- and oxygen-deficeint stress.   
Reduced amino acids or oxygen suppress the activity of mTOR, which is an anabolic 
kinase driving the energetically demanding growth of tumor cells [162]. Furthermore, 
inhibition of mTOR increases autophagy flux, which can engulf damaged organelle and 
cytosolic macromolecules and deliver them to lysosomes for degradation. In non–small-cell 
lung cancer (NSCLC) cells harboring oncogenic KRAS- or BRAF mutations, autophagy 
provides glutamine supply to maintain oxidative metabolism [163]. From the 1980s, 
scientists demonstrated that dysregulation of oncogenes and tumor suppressors were 
associated with tumor formation, leading to the identification of mutations as a cause of 
cancer [164]. Subsequent studies with extensive investigation using next-generation 
sequencing and omics-approaches discovered thousands of mutations for different cancer 
types. Therefore, cancer has been recognized as a complex genetic disease caused by the 
activation of oncogenes or loss of tumor suppressor genes, facilitating deregulation of cell 
proliferation and apoptosis. Extensive omics approaches have tried to identify the way to cure 
cancer by targeting the mutations driving the tumor growth. Furthermore, the considerable 
genetic and histological heterogeneity of tumors seems to converge into the common finite 
set of pathways to support fundamental functions such as catabolism, anabolism, and redox 
balance. This raises a question whether cancer metabolism itself can be targeted to control 
cancer growth. Finding a cure for cancer by regulating cancer metabolism have become a 
promising strategy [164].  
For targeting metabolism a few things have to be considered for the anti-metabolism 
drug development. First, proliferating cells, such as immune cells and stem cells, can 
reprogram their metabolic pattern similar to cancer cells [165, 166], which may limit the 
therapeutic feasibility of inhibiting certain metabolic enzymes. Additionally, the blockade of 
certain metabolic pathway may not be tolerated due to interference with the physiological 
functions of the normal tissues. Indeed, several excellent examples demonstrate the adequate 
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therapeutic window for targeting the reprogramming metabolic pathway, such as nucleotides 
synthesis by antifolates (methotrexate, pemetrexed). Second, cancer cells can utilize 
metabolic plasticity to reprogram their metabolic profile during metastasis and drug stress. 
Thus, it is conceivable that cancer cells could resist to inhibition of a particular metabolic 
pathway by upregulating compensatory pathways. Therefore, a reasonable therapeutic 
strategy should target several metabolic pathways simultaneously or target a particular 
metabolic pathway in combination with therapies to suppress compensatory signaling 
pathways.        
1.4.2 Energy metabolism in GIST 
GIST is generally recognized as a glycolysis-dependent tumor, which can be evaluated 
for the metabolic activity in FDG-PET scan. A few studies have investigated the energy 
metabolism in GIST, especially their regulation upon imatinib treatment [167]. Vitiello et al. 
found that imatinib suppresses glycolysis and induces OXPHOS-associated gene expressions. 
This study revealed the evidence of metabolic reprogramming toward OXPHOS upon imatinib 
stress and demonstrated the rationale of using a combination of OXPHOS inhibitor and 
imatinib for GIST therapy [168]. Our study further characterized the bioenergetic profile in 
imatinib-resistant GIST cells. We found that imatinib-resistant GIST cells can harbor high 
metabolic status (upregulated high glycolysis and OXPHOS status) and low OXPHOS status, 
suggesting the heterogeneity of metabolic reprogramming in GIST cells surviving imatinib 
cytotoxicity [169]. 
1.4.3 Energy metabolism in colorectal cancer (CRC) 
Several studies revealed upregulated OXPHOS in (CRC). A bioenergetic profiling study 
revealed a similar glycolytic activity and an upregulation of OXPHOS in CRC tissues 
compared to the surrounding healthy colon tissue [170]. The mitochondrial pyruvate carrier 
(MPC), a transporter for the mitochondrial uptake of pyruvate, was found to be upregulated in 
CRC and thereby abrogated the Warburg effect and facilitated the oxidative metabolism [171]. 
Chemoresistance to 5-fluorouracil (5-FU) in colon cancer cells exhibited upregulated 
OXPHOS and mitochondrial biomass and higher oxygen consumption rates via the histone 
deacetylase sirtuin-1 (SIRT1) and the downstream transcriptional coactivator PGC1α pathway 
[172]. The OXPHOS inhibitor metformin in combination with 5-FU showed a high sensitivity 
to the resistant colon cancer cells with stem-like features [173]. Furthermore, the different 
subgroups of CRC by molecular types demonstrated distinct types of energy metabolism. In 
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the BRAF or KRAS mutated tumors, metabolic reprogramming shifts from OXPHOS to a more 
glycolytic type [174].  
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2 AIMS OF THE THESIS 
 
The overall aim of this thesis work was to understand the roles of miRNA and energy 
metabolism in treatment response in gastrointestinal tumors. More specifically, we aimed to: 
 
Paper I: Identify the downstream target of miR-125a-5p-PTPN18 pathway in regulating 
imatinib response in GIST. 
 
Paper II: Characterize the bioenergetic profile of imatinib-resistant GIST.  
 
Paper III: Determine whether miRNAs are involved in imatinib-induced OXPHOS in GIST.  
 
Paper IV: Evaluate the association of metformin use with mortality in colorectal cancer 
patients. 
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3 MATERIALS AND METHODS 
3.1 CELL LINES 
Five established human GIST cell lines were included in this thesis. Two are imatinib-
sensitive cell lines. GIST 882 contains a homozygous missense mutation in KIT exon 13 
(K642E) (Papers I-III). GIST T1 has a heterozygous 57-bp deletion in KIT exon 11. Three 
imatinib-resistant cell lines GIST 882R (Papers I and II) and GIST T1R (Paper II), which 
were developed from parental GIST 882 and GIST T1 cells, and GIST 48, harboring a 
primary homozygous KIT exon 11 missense mutation (V560D) and a secondary 
heterozygous KIT exon 17 (D820A) mutation (Paper II). GIST 882 and GIST 48 were 
kindly provided by Dr. Jonathan Fletcher (Brigham and Women’s Hospital, Boston, MA, 
USA). GIST T1 was purchased from Cosmo Bio Co. Ltd. (Tokyo, Japan). The authenticity 
of the cell lines was confirmed by short tandem repeat (STR) genotyping, as described in 
Paper II. 
3.2 TUMOR SAMPLES 
In total, 64 snap-frozen tumors derived from 57 GIST patients were included in this 
thesis. Among these tumors, 30 had neoadjuvant imatinib treatment, referring to the imatinib-
treated group (Papers I-II), and 34 tumors were not treated with imatinib treatment prior to 
surgery (Papers II and III). Among the imatinib-treated group, 14 tumors were imatinib 
resistant, whereas 16 tumors were imatinib sensitive. The clinical, histopathological and 
follow-up details of the cases are detailed in Papers I-II and in [138].   
3.3 RNA DETECTION AND QUANTIFICATION METHODS 
Total RNA, including miRNA, was extracted by using miRVana miRNA isolation kit 
(Thermo Fisher Scientific, Waltham, MA). The RNA concentrations were determined by a 
NanoDrop spectrophotometer (NanoDrop technologies, Wilmington, DE). 
3.3.1 Reverse transcription-quantitative polymerase chain reaction 
 
Total RNA was reverse transcribed to first-strand cDNA using the TaqMan Multiscribe 
Reverse Transcription system. Two types of reverse transcription quantitative polymerase 
chain reaction (RT-qPCR), SYBR green and TaqMan assays, are reliable methods for RNA 
quantification. We have chosen the TaqMan assay (Applied Biosystems), which uses 
fluorophore (FAM)-labeled TaqMan probes to quantify the gene expression. The amount of 
FAM fluorescence signals during PCR amplification was measured as a function of PCR cycle 
number using an ABI 7900 Real-time PCR System (Applied Biosystems). This method was 
performed to detect miR-125a-5p and RNU6B in Paper I, and miR-320a, miR320b, miR-193a-
3p, miR-483-3p and RNU48 in Paper III. 
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3.3.2 miRNA microarray 
Global miRNA expression profiles in Paper III were determined using the Agilent 
human miRNA microarray platform (Agilent Technologies, Santa Clara, CA, USA). This 
platform provides high sensitivity and specificity using the unique design of the probes 
matching 903 human miRNAs (miRBase release 14).  
3.4 WESTERN BLOT ANALYSIS 
Western blot analysis is a widely used method for quantification and detection of specific 
proteins. Cells or tissue specimens were lysed in Nonidet-P40 (NP40) lysis buffer 
supplemented with 1 mM phenylmethysulfonyl fluoride and protease inhibitors. Lysates were 
loaded and separated using SDS-PAGE system with 10% or 4-12% Bis-Tris gels and then 
transferred to nitrocellulose membranes.  The membranes were blocked with 5% bovine serum 
albumin in Tris-buffered saline with 0.1% Tween-20, and then followed by incubating with 
primary antibodies for proteins of interest overnight at 4 oC. After washing, the membrane was 
incubated with host-matched secondary antibody at room temperature, and visualized by 
chemiluminescent or fluorescent detection. This method was used to analyze PTPN18, 
phosphorylated FAK (pFAK), FAK, and pSTAT3 (Paper I), AKT, phosphorylated AKT at 
Ser473, PGC1α, mitochondrial transcription factor A (TFAM), LDHA, LDHB, total OXPHOS, 
HK1, HK2, NRF1, NRF2, poly (ADP-ribose) polymerase (PARP) (Paper II) and SDHB 
(Paper III).  
3.5 TRANSFECTION 
 
Cell transfection is a method wherein foreign genetic molecules, such as synthesized or 
recombinant nucleic acids, are delivered into cells. The transfection methods include electrical 
transfection techniques such as electroporation, biochemical methods such as calcium 
phosphate co-precipitation, lipid-based reagents, and biologic methods such as virus-based 
vectors. Electroporation was used in this thesis for delivery of miRNA mimics/inhibitors and 
short hairpin RNA. We used Amaxa nucleofection system (Lonza), an electroporation method 
combined with a cell-specific transfection medium that facilitates nuclear delivery, especially 
suitable for difficult-to-transfect cells.  
3.5.1 miRNA mimics and inhibitors 
MiRNA mimics are chemically synthesized double-stranded RNA molecules that 
mimic endogenous mature miRNA. Anti-miR miRNA inhibitors are single-stranded nucleic 
acids designed to specifically bind to and inhibit endogenous miRNA. In Paper I
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mimics (pre-miR-125a-5p or pre-miR negative control) was transfected into GIST 882 cells. 
In paper III, miR-483-3p mimics and inhibitors were transfected into GIST 882 and GIST T1 
cells. 
3.5.2 Short hairpin RNA 
We used short hairpin RNA (shRNA) for silencing gene expression. shRNA targeting 
PTPN18 (target sequence: 5’-GAGGGACACAGCGACTACA-3’) was cloned into pcDNA3-
U6M2 vector [138]. Generally, a loop transcript consisting of sense and antisense sequences 
was generated upon transcription. The loop structure was recognized by the Dicer enzyme to 
produce mature active siRNA. In Paper I, shRNA against PTPN18 or vector control 
(shControl) was transfected into GIST 882 cells. 
3.5.3 Small interfering RNA 
Unlike shRNA as vector-based RNA interference, small interfering RNA (siRNA) is 
chemically synthesized double-stranded RNA. Although they are commonly used for gene 
knockdown, they are different in several ways. SiRNAs are oligonucleotides and thereby 
directly loaded into the RNA-induced silencing complex (RISC) in the cytoplasm, while 
shRNAs are transcribed in the nucleus and processed by Dicer before loading into RISC. 
Furthermore, siRNAs generally confer short-term effect, while shRNAs have longer-term 
effect and can be used for stable transfection.  
3.6 FUNCTIONAL ASSAYS 
In this thesis, several assays were used for studies of cell viability, proliferation, and apoptosis. 
3.6.1 Cell viability 
Cell viability can be measured using the metabolic activity in viable cells that reduces 
tetrazolium salts such as WST-1 ((4-(3-(4-iodophenyl)-2-(4nitrophenyl)-2H-5-tetrazolio)-1,3-
benzene disulfonate) into a colored soluble formazan dye. The colored dye allows 
quantification by spectrophotometer, which is proportional to the activity of the mitochondrial 
dehydrogenase system in viable cells. Comparing to other tetrazolium salts such as MTT and 
MTS, the WST-1 assay is less toxic, more sensitive and stable. The WST-1 assay was used in 
Paper I and Paper II. 
3.6.2 Cell proliferation 
Several assays are commonly used for cell proliferation analysis. First, DNA synthesis 
methods measure a labeled DNA analog or precursor such as 5-bromo-2’-deoxyuridine (BrdU) 
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or ethynyl-deoxyuridine (EdU), a pyrimidine analog or [3H]-thymidine incorporating into 
newly synthesized DNA during the S phase of the cell cycle. Second, IHC analysis for markers 
of proliferation can be applied such as Ki-67, proliferating cell nuclear antigen (PCNA), or 
minichromosome maintenance complex component (MCM). Moreover, real-time live cell 
imaging can also provide a measurement of the cell proliferation. For example, time-lapse 
phase-contrast imaging using Incucyte Live Cell Imaging (Essen Biosciences) can monitor the 
cell growth in a real-time manner. In this thesis, we used Incucyte imaging system to monitor 
the cell proliferation in Paper II.  
3.6.3 Apoptosis 
Apoptosis is a form of programmed cell death mediated by caspase activation upon 
external or internal stress. Several methods can assess the apoptotic cells such as microscopic 
morphology examination, terminal-deoxynucleotidyl transferase mediated nick end labelling 
(TUNEL) staining assay, Annexin V fluorescence staining, caspase-3 activity ELISA activity, 
JC-1 staining to detect mitochondrial membrane potential (MMP), and Western blot analysis 
for apoptotic markers. In this thesis, we used Annexin V/ propidium iodide (AV/PI) 
fluorescence staining (Paper II) and Western blotting for cleaved PARP1 (Papers I and II) 
to assess apoptosis. The AV/PI staining can be used to distinguish early stages of apoptosis 
(AV positive and PI negative) and late apoptosis/necrosis (both AV and PI positive). The 
externalization of phosphatidylserine on the cell membrane prior to the loss of cell membrane 
integrity during apoptosis can be recognized by AV and PI, respectively. Therefore, in early 
stage of apoptosis cells are AV positive and PI negative, while in late apoptosis cells are both 
positive for AV and PI. 
PARP-1, a key enzyme cleaves NAD+ into nicotinamide and ADP-ribose, is crucial 
for synthesis of protein-bound ADPR polymers upon single-strand DNA break. PARP-1 is a 
substrate of caspase-3. Therefore, the cleavage of PARP-1 is an indicator of apoptosis, which 
can be detected by Western blotting. 
3.7 METABOLIC ASSAYS 
In this thesis, we measured the glycolysis, OXPHOS, mitochondrial mass, and reactive oxygen 
species (ROS) using several different assays. 
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3.7.1 Mitochondrial bioenergetics 
The mitochondrial bioenergetics profile was performed by sequential injections of an 
ATP synthase inhibitor (oligomycin), a mitochondrial uncoupling agent (carbonyl cyanide-4-
(trifluoromethoxy)phenyl-hydrazone (FCCP), and respiratory chain inhibitors (antimycin A 
and rotenone). These serial additions can assess five mitochondrial oxygen consumption rates, 
including basal respiration, proton leak, ATP production, maximal respiration capacity, and 
spare respiratory capacity by using Seahorse XF96 analyzer. In Paper II, we used these 
parameters to assess the OXPHOS activity. 
3.7.2 Glycolysis activity 
Several assays can be used to monitor glycolysis. Extracellular glucose or lactate can be 
measured using spectrophotometry, which is simple and standard. Using extracellular 
bioanalyzer is also simple. Extracellular acidification rate (ECAR) measurement using 
seahorse XF analyzer can provide not only ECAR and simultaneous oxygen consumption rate 
(OCR) information. As lactate, the end product of glycolysis, is the source of acidification, we 
can measure ECAR to assess the glycolysis activity. We performed glycolysis stress test using 
Seahorse XF96 analyzer to measure the glycolysis activity in Paper II.   
3.7.3 Mitochondrial mass measurement 
Relative mitochondrial mass can be measured by the ratio of mitochondrial and nuclear 
DNA (mtDNA/nDNA), immunoblotting of key mitochondrial proteins, measuring 
mitochondrial protein content or weight after mitochondrial isolation, and MitoTracker Green. 
In this thesis, we measured mitochondrial mass of GIST cells by using MitoTracker Green, 
which is a mitochondrial mass-dependent fluorescence regardless of mitochondrial membrane 
potential, in Paper II. 
3.7.4 Intracellular reactive oxygen species  
Several assays can be used for measuring intracellular ROS such as Mito-SOX and 
dichlorodihydrofluorescein diacetate, which detects superoxide and hydrogen peroxide, 
respectively. In this thesis, we used dichlorodihydrofluorescein diacetate to assess whole-cell 
ROS level in Paper II. 
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3.7.5 Glucose uptake 
Two types of glucose analogs are commonly used for measuring glucose uptake. One is 
radioactive glucose analogs, such as 2-deoxy-d-[1,2-3H]-glucose (2-DG), or 2-deoxy-2-(18F)-
fluoro-d-glucose (18FDG). The other is fluorescent glucose analogs, such as 2-[N-(7-nitrobenz-
2-oxa-1,3-diaxol-4-yl)amino]-2-deoxyglucose (2-NBDG). In this thesis, we used 2-NBDG 
assay for glucose uptake measurement in Paper II. 
3.8 IMMUNOFLUORESCENCE 
Immunofluorescence can provide information about expression intensity and subcellular 
localization information of target proteins. We used immunofluorescence imaging for 
analyzing the expression and subcellular localization of PGC1α in Paper II. 
3.9 INHIBITION OF FAK PHOSPHORYLATION 
The phosphorylation sites of FAK include Tyr397, Tyr576/577, Tyr861, and Tyr925. 
FAK phosphorylated at Tyr397 is a major transducer to engage integrin-mediated survival 
signals. FAK Inhibitor 14 (Sigma) is a cell-permeable selective FAK inhibitor that specifically 
blocks phosphorylation of Tyr397. Therefore, we used this chemical for inhibition of FAK 
phosphorylation in Paper I.  
3.10 INHIBITION OF GLYCOLYSIS AND OXIDATIVE PHOSPHORYLATION 
Several classes of glycolysis inhibitors target different steps of glycolysis. For example, 
glucose analog 2-deoxyglucose (2-DG), 3-Bromopyruvate (3-BP) and lonidamine are HK2 
inhibitors, and 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) is a fructose 2,6-
bisphosphate (F-2,6-BP) inhibitor such as TEPP-46 and DASA-58 are small molecule 
inhibitors of pyruvate kinase isozyme 2 (PKM2). Lactate dehydrogenase (LDH) inhibitors 
include FX11, gossypol, and oxamate. In this thesis, we used 3-BP and gossypol for glycolysis 
inhibition in Paper II. 
There are several inhibitors target different OXPHOS complexes such as metformin and 
rotenone for Complex I, antimycin A for Complex III, sodium azide for Complex IV, or 
oligomycin for Complex V. We used oligomycin and antimycin A as the OXPHOS inhibitors 
in Paper II. 
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3.11 STATISTICAL ANALYSIS 
All statistical tests in this thesis were performed using GraphPad Prism 8.0 or Microsoft 
Office Excel 2010. For miRNA microarray analysis, Significance Analysis of Microarray 
(SAM) (http://statweb.stanford.edu/~tibs/SAM/) was used to determine the most significant 
differentially expressed miRNAs between the imatinib-treated and non-treated samples in 
Paper III. Statistical significance levels were assessed by using the false discovery rate (FDR). 
Independent Student’s t-test, Mann-Whitney U-test, or one-way ANOVA (more than two 
groups) was performed to compare the expression of miRNA and protein in different patient 
groups or cell lines (Papers I-III). Paired t-test was used to compare two different conditions 
between the experimental groups (Papers I and III). A two-way ANOVA was applied for 
more than two groups of two variables, followed by a post-hoc test (Dunnett’s). In Paper IV, 
baseline characteristics are shown as numbers and percentages for categorical variables and as 
medians and quantiles for continuous variables. Time-dependent Cox regression models were 
applied to obtain hazard ratios and 95% confidence intervals. Stabilized inverse probability of 
treatment weighting (IPTW) using propensity scores was used to balance baseline covariates 
between metformin users and nonusers. All p values are based on two-tailed tests. Significance 
is indicated as *** for p < 0.001, ** for p < 0.01, and * for p < 0.05.  
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4 RESULTS AND DISCUSSION 
4.1 MIR-125A-5P REGULATION OF FAK PHOSPHORYLATION IN IMATINIB 
RESISTANCE OF GASTROINTESTINAL STROMAL TUMORS (PAPER I) 
In our previous study, we identified miR-125a-5p as a regulator of imatinib response via 
targeting PTPN18. However, the downstream mechanism involved in altered imatinib response was 
not clear. FAK has been shown to play a significant role in promoting GIST progression and is 
associated with poor prognosis. We therefore investigated whether phosphorylation of FAK is the 
downstream target of PTPN18 and miR-125a-5p. 
4.1.1 Regulation of FAK phosphorylation by miR-125a-5p and PTPN18 
We found that silencing of PTPN18 by shPTPN18 upregulates the expression of pFAK but 
not phosphorylated STAT3. Similarly, siPTPN18 transfection using two different siRNAs also 
upregulated pFAK but not the total FAK level, suggesting that pFAK is the specific substrate of 
PTPN18. Furthermore, overexpression of miR-125a-5p led to increased expression of pFAK. These 
findings suggest that miR-125a-5p may upregulate pFAK via silencing of PTPN18.         
4.1.2 FAK phosphorylation and imatinib resistance in GIST 
In imatinib-resistant cell lines, we found that miR-125a-5p expressions were upregulated 
compared to their parental imatinib-sensitive cell line. Higher miR-125a-5p expression in the 
imatinib-resistant cell lines was concordant with lower PTPN18 and higher pFAK expressions. The 
FAK levels were similar between the imatinib-resistant and -sensitive cell lines. To test the role of 
pFAK, we used FAK inhibitor 14, an inhibitor of FAK that specifically blocks phosphorylation at 
tyrosine residue of codon 397. Inhibition of pFAK led to increased apoptosis and reduced cell 
viability in imatinib-resistant GIST cell lines, as evaluated by detection of cleaved PARP and WST-
1 assay, respectively. Furthermore, FAK inhibitor 14 could re-sensitize resistant cell lines to imatinib 
and reversed the imatinib resistance effect contributed by miR-125a-5p overexpression. These 
results suggest that FAK phosphorylation is critical in maintaining growth in imatinib-resistant 
GIST cells.   
4.1.3 Association of pFAK and FAK levels with clinical outcomes 
We further examined the association between FAK or pFAK and clinical outcomes. We found 
that upregulated FAK expression is associated with metastasis in GISTs, indicating its role in tumor 
progression. However, we did not find a significant association of pFAK with tumor progression, 
which is consistent with the study by Kamo et al. [175], suggesting that FAK may contribute to 
tumor progression in a kinase-independent manner.  
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In summary, we demonstrated the link between miR-125a-5p-PTPN18 axis and pFAK, which 
involves in regulating imatinib response in GIST cells. The total FAK level is associated with GIST 
tumor progression. 
4.2 METABOLIC HETEROGENEITY IN IMATINIB RESISTANT GIST (PAPER II) 
A previous study demonstrated that imatinib sensitive GIST cells undergo metabolic 
reprogramming to OXPHOS upon imatinib treatment, and inhibition of OXPHOS in combination 
with imatinib can enhance imatinib cytotoxicity. However, the bioenergetic profile of imatinib-
resistant GIST cells is not well understood. Therefore we further profiled the energy metabolism of 
imatinib-resistant GIST cells and investigated the effect of metabolic inhibitors on imatinib-resistant 
GIST cell lines.   
4.2.1 Effect of imatinib treatment on OXPHOS and mitochondrial biogenesis 
 First, we tested the effect of imatinib on metabolic reprogramming in imatinib-sensitive and 
-resistant GIST cell lines. OXPHOS proteins were increased in both imatinib-sensitive cell lines 
(GIST T1 and 882) upon imatinib treatment, which are consistent to the study by Vitiello et al.  [168]. 
However, no significant alteration of OXPHOS proteins were found in the imatinib-resistant GIST 
T1 and 882 cells upon imatinib treatment, suggesting that metabolic adaptation to imatinib did not 
occur in imatinib-resistant GIST. Since the mitochondrial biogenesis is closely correlated to 
OXPHOS activity, we further examined the mitochondrial mass and two key regulator proteins, 
mitochondrial transcription factor A (TFAM) and PGC1α using immunoblot analysis, 
immunofluorescence, and flow cytometry. We found that the expressions of TFAM and PGC1α 
were downregulated in both imatinib-sensitive cell lines upon imatinib treatment. However, the 
alterations were not consistent in imatinib-resistant GIST cell lines. In imatinib-resistant GIST T1 
cells, both TFAM and PGC1α expressions were downregulated, while no significant changes were 
found in GIST 882R cells. These findings may indicate different mitochondrial response to imatinib 
in resistant GIST cells. In clinical samples, we found significant downregulation of TFAM in both 
sensitive and resistant imatinib-treated GIST tumors. 
4.2.2 Metabolic heterogeneity in GIST cell lines and tumor samples 
We further characterized the energy metabolism of imatinib-resistant GIST cells, including 
two acquired resistant cell lines (GIST 882R and GIST T1R). We found that GIST 882R and GIST 
48 cells were more glycolytic than the parental GIST 882 cells. However, GIST T1R cells had 
similar basal glycolysis and less glycolytic activity than GIST T1 cells. Furthermore, GIST 882R 
cells also had more OXPHOS activities in terms of basal respiration and maximal respiratory 
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capacity compared with GIST 882 cells. On the other hand, GIST T1R cells had less OXPHOS 
activity than GIST T1 cells. These results suggest heterogeneity of metabolic reprogramming in 
imatinib-resistant GIST cells.  GIST 882R cells were highly metabolically active (glycolysis-high, 
OXPHOS-high) compared with GIST 882 cells, while reduced OXPHOS activity was found in 
GIST T1R cells. In concordance with the observation in cell lines, microarray expression profiles of 
15 imatinib-resistant GIST samples revealed two distinct clusters based on the expression of 
glycolysis and OXPHOS genes. One cluster displayed both higher expressions of glycolysis and 
OXPHOS genes, suggesting a highly metabolically active phenotype. The other cluster showed a 
relatively low OXPHOS status. Together, our results suggest metabolic heterogeneity in imatinib-
resistant GISTs.    
4.2.3 Inhibition of glycolysis and oxidative phosphorylation on cell viability 
Given that GIST 882R cells were more glycolytic than GIST 882 cells, we further tested 
whether they are more susceptible to glycolysis inhibitors. We found that 100 µM 3-BP, a 
hexokinase 2 inhibitor, induced significant apoptosis and inhibited the growth in GIST 882R cells 
and GIST 48 cells, but not in GIST 882 cells. Similarly, 10 µM gossypol, a LDHA inhibitor, reduced 
the proliferation of GIST 882R cells, but not GIST 882 cells. These results demonstrate that 
imatinib-resistant GIST cells with more glycolysis activity are vulnerable to inhibition of glycolysis. 
On the other hand, GIST T1R and GIST T1 cells did not show different cell growth upon 3-BP 
treatment. However, GIST T1R cells were more resistant to both antimycin A and oligomycin than 
GIST T1 cells.  
In summary, we found that resistant cells can manifest a highly metabolic active phenotype or 
a relatively low OXPHOS state, which results in differences for metabolic vulnerability in imatinib-
resistant GIST cells. 
4.3 IMATINIB INDUCED DOWNREGULATION OF MIR-483-3P AND 
UPREGULATION OF SDH IN GIST (PAPER III) 
 In Paper II, we found upregulation of OXPHOS in imatinib-sensitive GIST cells upon 
imatinib treatment.  This led us to further investigate the potential role of miRNAs in regulating 
OXPHOS. First we compared global miRNA expression profiles between imatinib-treated and 
untreated GIST samples. 
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4.3.1 Deregulation of miRNA induced by imatinib 
We characterized global miRNA expression profiles of 19 imatinib-treated and 15 untreated 
tumors using a microarray-based approach. Several miRNAs were deregulated in imatinib-treated 
tumors including overexpression of miR-320a, miR-320b and miR-193a-3p and reduced expression 
of miR-483-3p and miR-149. We confirmed significantly upregulation of miR-320b and 
downregulation of miR-483-3p in imatinib-treated tumors by RT-qPCR in an extended cohort. In 
concordance with the results of microarray and RT-qPCR, we found downregulation of miR-483-3p 
in GIST cells upon imatinib treatment. These results suggest that imatinib induces deregulation of 
selected miRNAs, which may participate in biological processes upon imatinib treatment, such as 
metabolic reprogramming to OXPHOS.   
4.3.2 miR-483-3p regulates Complex II expression 
 Overexpression of miR-483-3p suppressed, while inhibition of miR-483-3p upregulated 
Complex II expression, as indicated by increased SDHB expression. Of note, Complex III and V 
were not altered by modulation of miR-483-3p. We found an inverse relationship between miR-483-
3p and SDHB protein expression among GIST tumor samples. These results suggest that SDH may 
be a potential target of miR-483-3p. The mechanistic regulation between miR-483-3p and SDH 
warrants further investigation. 
4.4 METFORMIN ASSOCIATED WITH IMPROVING SURVIVAL IN CRC (PAPER IV) 
 Preclinical evidence indicates the anti-tumor effect of metformin in CRC. However, 
previous epidemiologic results remained controversial. Here we presented a large-scale nationwide 
cohort study to investigate the association of post-diagnostic metformin use with the mortality.  
4.4.1 Characteristics of metformin users versus nonusers 
 Between 2004 and 2014, 16,676 diabetic patients were diagnosed with CRC, including 
metformin nonusers (n = 5,238) and users (n = 11,438). We found that metformin users were 
younger, had lower score of comorbidities, and less advanced diseases. These results indicated that 
prescription of anti-diabetic medications may differ based on patients’ baseline characteristics. To 
reduce the baseline imbalance, we used the inverse probability of treatment weighting method in 
this study. 
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4.4.2 Metformin use and improving survival in patients with CRC 
 After adjustment for confounders and baseline characteristics using inverse probability of 
treatment weighting, metformin users had a 58% reduced risk of all-cause mortality than the 
nonusers. They also had a lower CRC-specific mortality with the hazard ratio of 0.41 (95%CI,  0.39-
0.44). The results were not altered across the subgroup analyses, indicating the consistent findings 
regardless of subpopulations. Overall, our conclusion suggests that metformin can be considered as 
an adjunct to the standard care in patients with CRC. 
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5 CONCLUSIONS  
In this thesis we provide insights into the role of miRNA and energy metabolism in regulating drug 
response in gastrointestinal malignancy. The main findings are as follows: 
• The miR-125a-5p-PTPN18 axis regulates imatinib response in GIST cells via targeting pFAK 
(Paper I). 
• Inhibition of pFAK can re-sensitize the imatinib resistance induced by overexpression of miR-
125a-5p (Paper I). 
•  Imatinib-resistant  GIST cells  manifest two distinct types of energy metabolism, one shows  a 
highly metabolically active phenotype and the other has low expression of OXPHOS (Paper 
II). 
• Imatinib-resistant GIST cells with higher glycolysis activity are more sensitive to glycolysis 
inhibitors compared with their parental GIST cells. Imatinib-resistant GIST cells with lower 
OXPHOS activity are more resistant to OXPHOS inhibitors than their parental cells (Paper II). 
• OXPHOS is upregaulted upon imatinib treatment in imatinib-sensitive GIST cells (Paper II). 
Selected miRNAs are deregulated, such as downregulated miR-483-3p, between imatinib-
treated and untreated GIST cells (Paper III).   
• miR-483-3p regulates the expression of SDH, which is the Complex II of the mitochondrial 
respiratory chain. Moreover, the expression of miR-483-3p was inversely correlated with SDH 
in GIST tumors (Paper III).  
• Postdiagnostic metformin use, an inhibitor of OXPHOS Complex I, is associated with better 
prognosis in diabetic patients with colorectal cancer (Paper IV).  
• Targeting energy metabolism and miRNA therapeutics can be potential to improve targeted 
drug resistance and survival in gastrointestinal malignancy. 
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